Background
Methods
Measurement of parasitaemia
Provision of malaria chemoprevention
Results
Village 1 (PLU) May 2010 | Village 2 (WLM) Dec 2011 | Village 3 (TMK) May 2012 | |
---|---|---|---|
Number of participants (% of total in population) | |||
Adult males | 177/193 (92 %) | 177/190 (93 %) | 75/160 (47 %) |
Adult females | 169/186 (91 %) | 146/201 (73 %) | 90/145 (62 %) |
Children | 234/255 (92 %) | 213/283 (75 %) | 236/373 (63 %) |
Total | 580/634 (91 %) | 536/674 (80 %) | 401/678 (60 %) |
Village 1 (PLU) May 2010 | Village 2 (WLM) Dec 2011 | Village 3 (TMK) May 2012 | |
---|---|---|---|
Number (%) positive for P. falciparum* | |||
Adult males | 2/176 (1.2 %) | 22/177 (12.4 %) | 6/75 (8.0 %) |
Adult females | 3/167 (1.7 %) | 2/146 (1.4 %) | 7/90 (7.8 %) |
Children | 0/234 (0 %) | 15/213 (7.0 %) | 28/236 (11.9 %) |
Total | 5/577** (0.9 %) | 39/536 (7.3 %) | 41/401 (10.2 %) |
Number (%) positive for P. vivax
*
| |||
Adult males | 29/176 (16.5 %) | 16/177 (9.0 %) | 13/75 (17.3 %) |
Adult females | 17*/167 (10.2 %) | 12/146 (8.2 %) | 9/90 (10.0 %) |
Children | 16/234 (6.8 %) | 33/213 (15.5 %) | 63/236 (26.7 %) |
Total | 62/577* (10.7 %) | 61/536 (11.4 %) | 85/401 (21.2 %) |
Village 1 (PLU) May 2010 | Village 2 (WLM) Dec 2011 | Village 3 (TMK) May 2012 | |
---|---|---|---|
Number (%) positive for P. falciparum* | |||
Adult males | 21/148 (14.2 %) | 42/171 (24.6 %) | 21/71 (29.6 %) |
Adult females | 18/127 (14.2 %) | 15/130 (11.5 %) | 18/90 (20.0 %) |
Children | 19/81 (23.5 %) | 14/84 (16.7 %) | 31/125 (24.8 %) |
Total | 58/356 (16.3 %) | 80/385 (18.4 %) | 71/286 (24.5 %) |
Number (%) positive for P. vivax* | |||
Adult males | 63/148 (42.5 %) | 56/171 (32.7 %) | 31/71 (43.7 %) |
Adult females | 39/127 (30.7 %) | 40/130 (30.8 %) | 32/90 (35.6 %) |
Children | 20/81 (24.7 %) | 46/84 (54.8 %) | 71/125 (56.8 %) |
Total | 122/356 (34.3 %) | 124/385 (36.9 %) | 134/286 (46.9 %) |
Village 1 (PLU) May 2010 | Village 2 (WLM) Dec 2011 | Village 3 (TMK) May 2012 | ||||
---|---|---|---|---|---|---|
Microscopy | PCR | Microscopy | PCR | Microscopy | PCR | |
Geometric mean (range) all species | 63.0 (32–256) | 7.82 (0.28–186,948) | 109 (16–5,888) | 50.31 (0.25–751,510) | 85.0 (2–4,224) | 26.07 (0.11–296,713) |
Geometric mean (range) P. falciparum
| 170.0 (90–256) | 2.95 (0.34–5,999) | 110 (16–5,792) | 69.52 (0.27–751,510) | 96.0 (16–4,224) | 79.01 (0.25–296,713) |
Geometric mean (range) P. vivax
| 47.9 (32–144) | 24.38 (0.31–25,136) | 109 (16–5,888) | 36.78 (0.3–108,318) | 79 (2–2,880) | 14.79 (0.11–97,719) |
After chemoprevention
June 2012 | July 2012 | August 2012 | December 2012 | |||||
---|---|---|---|---|---|---|---|---|
Number (%) of M/S* | Number (%) of PCR | Number (%) of M/S** | Number (%) of PCR | Number (%) of M/S | Number (%) of PCR | Number (%) of M/S*** | Number (%) of PCR | |
P. falciparum
| 8/560* (1.4 %) | 24/346 (6.9 %) | 0/409** (0.0 %) | 5/270 (1.9 %) | 1/263 (0.4 %) | 5/178 (2.8 %) | 1/425*** (0.2 %) | 1/370 (0 %) |
Adult male | 4/151 (2.6 %) | 8/72 (11.1 %) | 0/112 (0.0 %) | 1/60 (1.6 %) | 1/76 (1.3 %) | 3/42 (7.1 %) | 1/93 (1.1 %) | 0/92 (0.0 %) |
Adult female | 1/171 (0.6 %) | 8/121 (6.6 %) | 0/117 (0.0 %) | 0/96 (0.0 %) | 0/75 (0.0 %) | 1/58 (1.7 %) | 0/134 (0.0 %) | 0/133 (0.0 %) |
Child | 3/238 (1.3 %) | 8/153 (5.2 %) | 0/180 (0.0 %) | 4/114 (3.5 %) | 0/112 (0.0 %) | 1/78 (1.3 %) | 0/198 (0.0 %) | 0/145 (0.0 %) |
P. vivax
| 61/560 (10.9 %) | 122/346 (35.5 %) | 18/409 (4.4 %) | 45/270 (16.7 %) | 14/263 (5.3 %) | 30/178 (16.9 %) | 37/425 (8.7 %) | 29/370 (7.8 %) |
Adult male | 16/151 (10.6 %) | 23/72 (31.9 %) | 1/112 (0.9 %) | 4/60 (6.7 %) | 2/76 (2.6 %) | 3/42 (7.1 %) | 7/93 (7.5 %) | 4/92 (4.3 %) |
Adult female | 9/171 (5.3 %) | 35/121 (28.9 %) | 1/117 (0.9 %) | 2/96 (2.1 %) | 1/75 (1.3 %) | 2/58 (3.4 %) | 7/134 (5.2 %) | 7/133 (5.3 %) |
Child | 36/238 (15.1 %) | 64/153 (41.8 %) | 16/180 (8.9 %) | 39/114 (34.1 %) | 11/112 (9.8 %) | 25/78 (32.0 %) | 23/198 (11.6 %) | 18/145 (12.4 %) |
Indeterminate | NA | 57/346 (16.5 %) | NA | 27/270 (10.0 %) | NA | 27/178 (15.2 %) | NA | 15/370 (4.1 %) |
Adult male | NA | 12/72 (16.7 %) | NA | 7/60 (11.7 %) | NA | 11/42 (26.2 %) | NA | 4/92 (4.3 %) |
Adult female | NA | 23/121 (19.0 %) | NA | 6/96 (6.3 %) | NA | 5/58 (8.6 %) | NA | 0/133 (0.0 %) |
Child | NA | 22/153 (14.4 %) | NA | 14/114 (12.3 %) | NA | 11/78 (14.1 %) | NA | 6/145 (4.1 %) |
Negative | 493/560 (88.0 %) | 153/346 (44.2 %) | 391/409 (95.6 %) | 196/270 (72.6 %) | 248/263 (94.3 %) | 117/178 (65.7 %) | 387/425 (91.1 %) | 326/370 (88.1 %) |
Adult male | 131/151 (86.8 %) | 32/72 (44.4 %) | 111/112 (99.1 %) | 48/60 (80.0 %) | 73/76 (96.1 %) | 25/42 (59.5 %) | 85/93 (91.4 %) | 84/92 (91.3 %) |
Adult female | 111/171 (94.7 %) | 56/121 (46.2 %) | 116/117 (99.1 %) | 88/96 (91.7 %) | 74/75 (98.7 %) | 50/58 (86.2 %) | 127/134 (94.8 %) | 126/133 (94.7 %) |
Child | 73/238 (84.0 %) | 65/153 (42.5 %) | 164/180 (91.1 %) | 60/114 (52.6 %) | 104/112 (90.2 %) | 42/78 (53.8 %) | 175/198 (88.4 %) | 121/145 (83.4 %) |
Case | Dec 2011 | June 2012 | July 2012 | August 2012 | Dec 2012 | |||
---|---|---|---|---|---|---|---|---|
PCR result | MDA | PCR result | MDA | PCR result | MDA | PCR result | PCR result | |
1 | PF | Y | PF | N | N | N | N | Neg |
2 | PF/PV | N | PF/PV | N | PF/PV | N | N | Neg |
3 | PF | Y | PF | Y | Neg | N | N | Neg |
4 | PF/PV | N | PV | N | Neg | N | Neg | PV |
5 | PF | Y | NEG | Y | Neg | N | N | Neg |
6 | PF/PV | N | PF/PV | N | PF/PV | N | Indeterminate | PV |
7 | PF/PV | N | PF | N | N | Y | PV | Neg |
8 | PF/PV | Y | PV | Y | PV | N | N | Neg |